Drug intelligence / Profile preview

warfarin + vitamin k + midazolam

Development stage: Unknown
Lead developer: Wisconsin Alumni Research Foundation
Modality: Small Molecules
Administration: Oral

Overview

A drug combination used primarily in clinical research settings for phenotypic assessment of multiple cytochrome P450 enzymes. Warfarin serves as a biomarker for CYP2C9 activity, while vitamin K is co-administered to ablate warfarin's pharmacodynamic anticoagulant effects. Midazolam is included as a probe for hepatic CYP3A activity. This combination allows for simultaneous assessment of multiple drug-metabolizing enzymes in clinical pharmacology studies.

Other names: Cooperstown 5+1 cocktail

Targets

CYP3A4 (Cytochrome P450 3A4)VKORC1 (Vitamin K epoxide reductase complex subunit 1)GABRR (GABA-A receptor subunit rho)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)

Beyond the preview

Go deeper on warfarin + vitamin k + midazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on warfarin + vitamin k + midazolam.

Explore the full profile